Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective

Cancers

Anna Szumera-Ciećkiewicz¹  Mateusz J. Spałek²  Iga Płachta²  Marcin Kleibert²  Anna M. Czarnecka²  Piotr Rutkowski² 

[1] Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland;Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research, Institute of Oncology, 02-781 Warsaw, Poland;

关键词: radiotherapy;    rare skin cancer;    sebaceous;    follicular;    apocrine;    eccrine;   

DOI  :  10.3390/cancers14040998

来源: DOAJ

【 摘 要 】

Malignant adnexal cancers of the skin—extremely rare neoplasms—are mostly reported as non-symptomatic, slow-growing nodules. These carcinomas occur mainly in the middle-aged (50–60 years of age); they are mostly localized on the upper part of the body and are locally aggressive, infiltrate surrounding tissue, and metastasize to regional lymph nodes. The patients’ outcomes depend on multiple prognostic factors, including the size of the primary tumor and its mitotic count. Surgical resection of the primary tumor with or without regional lymph nodes is the treatment method of choice; however, due to aggressive tumor behavior, perioperative treatment may be considered. The role and efficacy of radiotherapy in the treatment of skin adnexal malignancies are not yet fully defined. Some authors suggest that adjuvant radiotherapy may be considered in locally advanced and regional disease. The aim of this study was to evaluate treatment outcomes and assess the efficacy of combined therapy in patients with adnexal malignancies. Our analysis covered all cases of cutaneous adnexal tumor patients diagnosed and provided with multidisciplinary treatment with surgery and radiotherapy since the beginning of 2009.

【 授权许可】

Unknown